Online inquiry

IVTScrip™ mRNA-Anti-IL31RA, CIM 331(Cap 0, 2-Thio-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ5909MR)

This product GTTS-WQ5909MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 0 & 2-Thio-UTP. It ecodes the monoclonal antibody that targets IL31RA gene. The antibody can be applied in Atopic dermatitis (AD) research.
Specifications
Product type mRNA
Modified bases 2-Thio-UTP
5' Cap Cap 0
Species Humanized
RefSeq NM_001242636.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 133396
UniProt ID Q8NI17
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-IL31RA, CIM 331(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) (GTTS-WQ5909MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT Product Name Product Type CDs
GTTS-WQ6708MR IVTScrip™ mRNA-Anti-EGFR, DS 1024(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA DS 1024
GTTS-WQ15377MR IVTScrip™ mRNA-Anti-CD37, TRU-016(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA TRU-016
GTTS-WQ11391MR IVTScrip™ mRNA-Anti-PDGFRA, MEDI-575(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA MEDI-575
GTTS-WQ13374MR IVTScrip™ mRNA-Anti-LRRC15, PR-1498487(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA PR-1498487
GTTS-WQ1367MR IVTScrip™ mRNA-Anti-IL12B, ABT-874(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA ABT-874
GTTS-WQ10828MR IVTScrip™ mRNA-Anti-PD-L1&TGFBR2, M7824(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA M7824
GTTS-WQ3263MR IVTScrip™ mRNA-Anti-TNF, ART621(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA ART621
GTTS-WQ13771MR IVTScrip™ mRNA-Anti-MSTN, REGN-1033(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA REGN-1033
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW